Ownership and insider activity for TuHURA Biosciences, Inc. (HURA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Price
| Price | $2.03 |
| Market Cap | $129M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-28 | Bianco James A. | G-Gift | 150,000 | |
| 2026-02-12 | Tendler Craig | A-Award | 156,240 | $202K |
| 2026-02-12 | Ng George K | A-Award | 156,240 | $202K |
| 2026-02-12 | MANUSO JAMES S J | A-Award | 156,240 | $202K |
| 2026-02-12 | List Alan | A-Award | 156,240 | $202K |
| 2026-02-12 | Hoffman Robert E. | A-Award | 156,240 | $202K |
| 2026-01-06 | Dearborn Dan | A-Award | 273,696 | $200K |
| 2026-01-06 | Bianco James A. | A-Award | 610,332 | $446K |
| 2025-12-12 | Dearborn Dan | A-Award | 1,531,367 | $1.6M |
| 2025-12-12 | Bianco James A. | A-Award | 3,414,891 | $3.5M |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.6M | $6.0M | $3.7M | $2.4M | $10.5M | $5.5M | $14.3M | $3.7M | $12.7M | $3.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $76595 | $39519 | $26187 | 0 | 0 | 0 | $101424 | $334443 | $222702 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $214699 | 0 |
| Total Current Assets | $7.9M | $7.0M | $4.0M | $2.8M | $11.8M | $5.7M | $14.7M | $4.2M | $19.6M | $4.6M |
| Property, Plant & Equipment | 0 | 0 | 0 | $2000 | $150000 | $617139 | $418547 | $202990 | $322526 | $685169 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $10.7M |
| Intangible Assets | $40290 | $28411 | $12062 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $7.9M | $7.1M | $4.0M | $2.9M | $13.5M | $6.4M | $15.2M | $4.4M | $20.0M | $27.4M |
| Accounts Payable | $1.3M | $1.5M | $1.7M | $2.0M | $2.2M | $413794 | $1.9M | $1.9M | $3.2M | $3.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $644070 | 0 | 0 | 0 | $197354 |
| Total Current Liabilities | $1.3M | $1.6M | $2.1M | $2.7M | $2.8M | $7.2M | $2.9M | $3.6M | $5.3M | $5.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $2.3M | 0 | $303627 |
| Total Liabilities | $1.3M | $1.6M | $2.1M | $2.7M | $3.0M | $7.2M | $2.9M | $5.9M | $5.4M | $6.4M |
| Retained Earnings | -$41.1M | -$52.4M | -$60.6M | -$69.7M | -$111.2M | -$49.5M | -$59.2M | -$88.5M | -$111.1M | -$141.2M |
| Total Equity | $6.6M | $5.4M | $2.0M | $263000 | $10.6M | -$747821 | $12.3M | -$1.6M | $14.6M | $20.9M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | $644070 | $138224 | $2.3M | $202542 | $700022 |
| Net Debt | -$6.6M | -$6.0M | -$3.7M | -$2.4M | -$10.5M | -$4.9M | -$14.1M | -$1.3M | -$12.5M | -$2.9M |
| Working Capital | $6.6M | $5.4M | $2.0M | $82000 | $9.0M | -$1.5M | $11.9M | $562422 | $14.3M | -$1.3M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 0.18 |
Profitability
| Return on Equity | -154.32% |
| Return on Invested Capital | -137.40% |
| Return on Assets | -96.49% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABOS · AGEN · CGTX · INO · IRD · MCRB · SEER
Explore sector: Healthcare · Biotechnology
More sections of HURA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks